Arsinothricin Antibiotic Strategy Against Drug-Resistant Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of drug-resistant bacteria has rendered many clinically used antibiotics ineffective, particularly for infections caused by pathogens such as Mycobacterium tuberculosis and other antibiotic-resistant bacteria, necessitating the development of new antibiotics.
Innovation Solution
Arsinothricin, a broad-spectrum antibiotic derived from a soil bacterium, is administered alone or in combination with an inhibitor of phosphinothricin N-acetyltransferase to treat infections caused by bacteria, protozoa, helminths, and fungi, including drug-resistant strains like Mycobacterium tuberculosis, by inhibiting bacterial glutamine synthetase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat infections, then infections can be treated, but drug-resistant bacteria emerge and render the antibiotics ineffective
Solution Approach 1:
The patent changes the chemical structure and mechanism of action parameters by using arsinothricin, an organoarsenical compound that inhibits glutamine synthetase, fundamentally altering how the antibiotic attacks the bacterial cell compared to conventional agents
Solution Approach 2:
The patent exploits the bacterial cell's own glutamine synthetase enzyme, which is essential for bacterial growth, and converts it into a vulnerability by designing a compound that specifically inhibits this enzyme, turning a beneficial bacterial process into a target for destruction
2Adaptability or versatility
If new antibiotics are developed to address drug-resistant bacteria, then treatment options expand, but the complexity of developing and testing new antibiotics increases
Solution Approach 1:
The patent demonstrates that arsinothricin has broad-spectrum activity against multiple types of bacteria including Gram-positive, Gram-negative, and mycobacteria, making a single compound effective against diverse pathogens and reducing the need for multiple specialized drugs
Solution Approach 2:
The patent identifies glutamine synthetase as an intermediary target enzyme that is universally present in bacteria but absent or different in humans, serving as a selective vulnerability that enables antibiotic development with reduced side effects
3Reliability
If arsinothricin is used to treat infections, then drug-resistant pathogens are effectively treated, but the mechanism of action and potential side effects must be carefully managed
Solution Approach 1:
The patent achieves selective toxicity by targeting a specific bacterial enzyme (glutamine synthetase) that has a different structure and function in humans, creating a local quality difference that allows the drug to be effective against bacteria while minimizing harm to human cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Arsinothricin effectively treats a wide range of infections, including those resistant to multiple antibiotics, by leveraging the arsN1 gene's resistance mechanism and inhibiting bacterial glutamine synthetase, providing a novel approach to combat drug-resistant pathogens.
Implementation Method 1
Arsinothricin is a broad-spectrum antibiotic derived from a soil bacterium, is administered alone or in combination with an inhibitor of phosphinothricin N-acetyltransferase to treat infections caused by bacteria, protozoa, helminths, and fungi, including drug-resistant strains like Mycobacterium tuberculosis, by inhibiting bacterial glutamine synthetase
Implementation Method 2
In certain embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase, and the method further comprises administering to the subject an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase
Data Source
AI summary
Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli, the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium bovis, or Enterobacter cloacae. The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. Further embodiments provide compositions comprising arsinothricin or a salt thereof and an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.